Detalhe da pesquisa
1.
Two-Pore Domain Potassium Channels as Drug Targets: Anesthesia and Beyond.
Annu Rev Pharmacol Toxicol
; 61: 401-420, 2021 01 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32679007
2.
Pharmacological Approaches to Studying Potassium Channels.
Handb Exp Pharmacol
; 267: 83-111, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34195873
3.
Opportunistic screening for atrial fibrillation by clinical pharmacists in UK general practice during the influenza vaccination season: A cross-sectional feasibility study.
PLoS Med
; 17(7): e1003197, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32678820
4.
Characterization and regulation of wild-type and mutant TASK-1 two pore domain potassium channels indicated in pulmonary arterial hypertension.
J Physiol
; 597(4): 1087-1101, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30365877
5.
Pranlukast is a novel small molecule activator of the two-pore domain potassium channel TREK2.
Biochem Biophys Res Commun
; 520(1): 35-40, 2019 11 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-31564414
6.
Terbinafine is a novel and selective activator of the two-pore domain potassium channel TASK3.
Biochem Biophys Res Commun
; 493(1): 444-450, 2017 11 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28882594
7.
TASK-1 (KCNK3) channels in the lung: from cell biology to clinical implications.
Eur Respir J
; 50(5)2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29122916
8.
Enhancement of TWIK-related acid-sensitive potassium channel 3 (TASK3) two-pore domain potassium channel activity by tumor necrosis factor α.
J Biol Chem
; 289(3): 1388-401, 2014 Jan 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-24307172
9.
Two-pore domain potassium channels: potential therapeutic targets for the treatment of pain.
Pflugers Arch
; 467(5): 931-43, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25420526
10.
Recovery of current through mutated TASK3 potassium channels underlying Birk Barel syndrome.
Mol Pharmacol
; 85(3): 397-407, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24342771
11.
Influence of the N terminus on the biophysical properties and pharmacology of TREK1 potassium channels.
Mol Pharmacol
; 85(5): 671-81, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24509840
12.
The Concise Guide to PHARMACOLOGY 2023/24: Nuclear hormone receptors.
Br J Pharmacol
; 180 Suppl 2: S223-S240, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38123152
13.
The Concise Guide to PHARMACOLOGY 2023/24: Enzymes.
Br J Pharmacol
; 180 Suppl 2: S289-S373, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38123154
14.
The Concise Guide to PHARMACOLOGY 2023/24: Transporters.
Br J Pharmacol
; 180 Suppl 2: S374-S469, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38123156
15.
The Concise Guide to PHARMACOLOGY 2023/24: Catalytic receptors.
Br J Pharmacol
; 180 Suppl 2: S241-S288, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38123155
16.
The Concise Guide to PHARMACOLOGY 2023/24: Introduction and Other Protein Targets.
Br J Pharmacol
; 180 Suppl 2: S1-S22, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38123153
17.
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors.
Br J Pharmacol
; 180 Suppl 2: S23-S144, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38123151
18.
The Concise Guide to PHARMACOLOGY 2023/24: Ion channels.
Br J Pharmacol
; 180 Suppl 2: S145-S222, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38123150
19.
A KCNB1 gain of function variant causes developmental delay and speech apraxia but not seizures.
Front Pharmacol
; 13: 1093313, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36618935
20.
Gain and loss of TASK3 channel function and its regulation by novel variation cause KCNK9 imprinting syndrome.
Genome Med
; 14(1): 62, 2022 06 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35698242